China SXT Pharmaceuticals, Inc. Ordinary Shares
SXTCChina SXT Pharmaceuticals, Inc. is a China-based clinical-stage biotechnology company focused on the development of innovative therapies. The company specializes in the research and development of pharmacological products targeting various medical conditions, with an emphasis on improving treatment outcomes through novel drug candidates.
Company News
Univest Securities completed a $10 million registered direct offering for China SXT Pharmaceuticals (NASDAQ: SXTC), a specialty pharmaceutical company focused on Traditional Chinese Medicine products. The company sold approximately 66.67 million Class A ordinary shares at $0.15 per share to a single investor.
China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced a registered direct offering of 66.67 million Class A ordinary shares at $0.15 per share, expected to raise approximately $10 million. The transaction is expected to close on January 12, 2026. The company is a specialty pharmaceutical firm focused on traditional Chinese medicine products.
China SXT Pharmaceuticals, Inc. (SXTC) announced a 1-for-8 share consolidation to regain compliance with the Nasdaq's minimum bid price requirement of $1.00 per share. The company's shares will begin trading on a post-consolidation basis on February 25, 2025.
Ericsson reported better-than-expected Q2 sales and issued guidance, causing its shares to rise in pre-market trading. Several other stocks also saw significant pre-market movement, both positive and negative.
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. Core income per share reached $4.69 from $4.11 a year ago, missing the $4.90 consensus forecast. Net income per share rose to $4.80 ...
